Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA - Seite 3

About Sandoz
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.

# # #

For further information:

Eric Althoff Novartis Global Media Relations [phone] [phone] [e-mail]	Sreejit Mohan Sandoz Global Communications [phone] [e-mail]

Novartis Investor Relations

Central phone:	[phone]	North America:
Samir Shah	[phone]	Richard Pulik	[phone]
Pierre-Michel Bringer	[phone]	Sloan Pavsner	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]
e-mail: [e-mail]

©2015 Sandoz Inc. All rights reserved.